HHS implements interim policy for compounding specific unapproved peptides

The U.S. Department of Health and Human Services (HHS) issued an interim policy allowing state-licensed pharmacies, federal facilities, and physicians to compound six unapproved peptides, including BPC-157, without federal enforcement. This aims to regulate the market by requiring patient-specific prescriptions, traceable ingredients, quality testing, and safety reporting, offering a controlled alternative to unregulated online sales.